Collegium Pharmaceutical, Inc. Q4 2025 Earnings Call Summary

Core Insights - The company achieved record full-year net revenues of $780.6 million, representing a 24% increase driven by the first full year of Jornay PM ownership and continued growth in the core pain portfolio [1] - Jornay PM delivered 48% revenue growth compared to pro forma 2024, supported by a strong back-to-school season and the initial impact of sales force expansion from 125 to 180 representatives [1] - The pain portfolio, which includes Belbuca, Xtampza ER, and Nucynta, grew 6% year-over-year to $631.7 million, reinforcing management's view that these revenues are more durable than market expectations [1] Financial and Operational Highlights - The company successfully transitioned the Nucynta franchise to an authorized generic (AG) model with Hikma Pharmaceuticals, utilizing a profit-share structure to maintain value against third-party generic competition [1] - The balance sheet was strengthened by closing a $980 million syndicated credit facility, reducing interest costs and providing nearly $400 million in additional liquidity for future portfolio diversification [1] - Operational efficiency enabled the company to reach a net leverage ratio of less than 1 time, meeting an ambitious deleveraging target set earlier in the year [1]